| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Departments of * Pharmacology and
Therapeutics and Obstetrics and Gynecology,
McGill University, Montreal, Canada.
| Correspondence to: Dr B. F. Hales, Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir-William-Osler, Montreal, Canada H3G 1Y6 (e-mail: barbara.hales{at}mcgill.ca). |
| Received for publication November 6, 2003; accepted for publication December 8, 2003. |
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
Key words: Sperm, comet assay, chromatin remodeling, susceptibility, toxicology
Among the commonly used anticancer drugs, alkylating agents have been associated most often with the development of infertility (Schilsky, 1980; Pont, 1997). Cyclophosphamide is a cytotoxic alkylating agent widely used in chemotherapeutic regimens. Its cytotoxic effects are the result of chemically reactive metabolites that create DNA adducts, DNA-DNA and DNA-protein crosslinks, sister chromatid exchanges, chromosomal aberrations, and DNA strand breaks (Sotomayor and Cumming, 1975; Bishop et al, 1997). Exposure of male germ cells to cyclophosphamide leads to single-strand breaks, crosslinks, and altered in vitro spermatozoal decondensation and template function (Qiu et al, 1995a,b). With little effect on the male reproductive system, chronic paternal treatment of rats with cyclophosphamide results in increases in embryo death and growth-retarded and malformed fetuses (Trasler et al, 1985, 1986, 1987; Jenkinson and Anderson, 1990). Although proliferating premeiotic germ cells are sensitive to alkylating agents, nondividing postmeiotic spermatids and spermatozoa are the most susceptible to DNA damage, leading to dominant lethality, heritable translocations, specific locus mutations, and malformations (Jackson, 1964; Ehling et al, 1968). Certain monofunctional alkylating agents, such as methyl methanesulfonate and ethylene oxide, produce more dominant lethal mutations and translocations in late spermatids and early spermatozoa than in any other germ cell stage (Ehling, 1980; Generoso et al, 1980). In contrast, other chemicals, such as ethyl nitrosourea and methyl nitrosourea, show no germ cell stage–specific selection, with a wide range of effects on both pre- and postmeiotic germ cells (Russell et al, 1979; Sega et al, 1981). Cross-linking agents are also active throughout spermatogenesis; however, maximal genetic damage has been observed in early round spermatids (Russell, 1989, 1992). Dramatic increases in postimplantation loss are dose-dependent and maximal after a 3-week treatment of male rats with a low dose of cyclophosphamide (Trasler et al, 1985, 1986, 1987), which thereby exposes germ cells during spermiogenesis and sperm maturation.
Abnormal sperm chromatin packaging, identified as poorly protaminated spermatozoa or a high susceptibility of DNA to acid-induced denaturation using the sperm chromatin structure assay, has been correlated with the presence of DNA strand breaks (Gorczyca et al, 1993; Manicardi et al, 1995, 1998; Sailer et al, 1995). Mature spermatozoa contain highly packaged chromatin organized in a specific manner to allow access to required genetic information during embryogenesis. The proposed model for sperm DNA packaging consists of several levels of organization, including DNA loop domains attached to the nuclear matrix in a sequence-specific manner (Ward and Coffey, 1991; Ward, 1993) and protamine DNA binding (Balhorn, 1982). With such an intricate organization of the sperm nucleus, the possibility exists that damage to the DNA will, in turn, affect overall nuclear organization. Continuous treatment with cyclophosphamide for 4 weeks targets the male germ cell through all stages of spermiogenesis and sperm maturation. The adverse progeny outcomes associated with paternal exposure to this drug may be due to the accumulation of DNA damage in male germ cells as round spermatids develop into spermatozoa or due to spermiogenic germ cell phase–specific susceptibility to damage.
Genotoxic damage in the form of single- and double-stranded breaks can be measured using the comet assay. This assay is used extensively to assess DNA damage in somatic cells and has been applied to human and murine spermatozoa (Singh et al, 1989; Haines et al, 1998; Tice et al, 2000). Increased DNA damage in human spermatozoa measured by the comet assay is associated with infertility (Irvine et al, 2000) and exposure to chemotherapeutic agents (Chatterjee et al, 2000). In this study, we have developed the comet assay under alkaline conditions for rodent spermatozoa. We have used this assay to determine to what extent and at which point during spermiogenesis sperm acquire DNA damage after acute, subchronic, and chronic dosing regimens with cyclophosphamide.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Sperm Collection
To isolate spermatozoa from the cauda epididymides, the epididymides were
first removed, trimmed free of fat, and washed in 2 mL of prewarmed (37°C)
10 mM Tris-HCl buffer containing 50 mM NaCl and 50 mM EGTA, pH 8.2–8.4.
This medium maintains the genetic integrity of frozen spermatozoa
(Kusakabe et al, 2001). The
corpus–cauda epididymal junction was then clamped with a hemostat, and
an incision was made in the distal cauda epididymidis. Spermatozoa released
from the site of incision were collected in 2 mL of media at 37°C,
incubated for 5 minutes to allow the spermatozoa to disperse, and then diluted
1:10 in fresh media. Aliquots of 100 µL were stored at –80°C
until comet analysis was performed.
Detection of Damage in Individual Cells Using the Comet Assay
DNA damage in spermatozoa was evaluated using the comet assay as previously
described (Singh et al, 1989;
Haines et al, 1998) with the
following modifications. Frozen sperm samples were thawed on ice and
resuspended in Tris-HCl–buffered EGTA medium to a concentration of 1
x 105 cells/mL. Fifty microliters of the cell suspension was
added to 500 µL of molten agarose (0.5% low-melting-point grade in
Mg2+ and Ca2+—free phosphate-buffered saline, pH
7.4, at 42°C). Sixty microliters was immediately pipetted and evenly
spread onto slides (Trevigen Inc, Gaithersburg, Md), and the gel was allowed
to solidify at 4°C in the dark for 10 minutes. All subsequent steps were
performed under yellow light or in the dark to prevent any additional DNA
damage.
Slides were immersed in prechilled (4°C) lysis buffer (2.5 M NaCl, 100 mM EDTA, and 10 mM Tris-HCl; final pH, 10) containing 10% dimethylsulfoxide, 1% Triton X-100, and 40 mM dithiothreitol for 1 hour on ice. Following initial lysis, slides were washed in distilled water for 5 minutes. Proteinase K, at a concentration of 0.1 mg/mL, was added to fresh prewarmed lysis buffer, and additional lysis was performed for 3 hours at 37°C. Slides were washed in distilled water, placed flat at 4°C for 10 minutes to reset the agarose, and then immersed in freshly prepared alkaline solution (1 mM EDTA and 0.05 M NaOH, pH 12.1) for 45 minutes in the dark. Slides were washed twice in 1x Tris-Borate-EDTA buffer (TBE, pH 7.4) for 5 minutes and then placed equidistant from the electrodes on a gel tray submerged in TBE in a horizontal electrophoresis apparatus (Mini-Sub Cell GT; Bio-Rad Laboratories, Inc, Mississauga, Canada). The level of TBE was 2–4 mm above the slides. Electrophoresis was carried out at 14 V (0.7 V/cm) for 10 minutes. Slides were drained and fixed in ice-cold 70% ethanol for 5 minutes and left to air dry prior to storage with desiccant at room temperature. Similar to the standard alkaline comet assay defined by Singh et al (1988), treatment with alkali to unwind and denature the DNA followed by electrophoresis in neutral buffer permits the detection of single-strand breaks. These conditions, however, tend to give lower background levels of DNA damage, result in better dose responses, and avoid saturating the assay so that estimation of damage is over a wider range (Koppen and Angelis, 1998; Angelis et al, 1999).
DNA was stained with 50 µL of SYBR Green solution (Trevigen) diluted 1:10 000 in Tris-EDTA buffer, pH 7.5, and immediately analyzed at 200x magnification using a DAGE-MTI CCD300-RC camera (DAGE-MTI Inc, Michigan City, Ind) attached to an Olympus BX51 epifluorescence microscope. Fifty cells were randomly analyzed per slide for a total of 100 cells per animal, and fluorescent images were scored for comet parameters. Tail length, percent tail DNA, and tail moment (tail length x fraction of tail DNA) were measured using the KO-MET 5.0 image analysis system (Kinetic Imaging Ltd, Liverpool, United Kingdom).
Statistical Analysis
Significant differences due to drug treatment or time of drug exposure were
determined using a 2-way analysis of variance followed by the Bonferroni post
hoc test (P < .05). The percent abnormal sperm among populations
of spermatozoa from saline- and cyclophosphamide-treated animals was compared
by chisquare analysis. Statistical analyses were performed by the SigmaStat
2.03 software package (SPSS Inc, Chicago, Ill).
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
|
Acute 1-Day Exposure
Exposure of male germ cells to a single high dose of cyclophosphamide
resulted in time-specific increases in DNA damage
(Figure 2). Small yet
significant differences were observed only in the percentage of tail DNA
values 14 days after drug administration (1.4-fold increase) and in tail
length values after 14 days (1.2-fold increase) and 21 days (1.7-fold
increase). On the integration of these 2 comet parameters to obtain the tail
moment, significant differences between drug-exposed and time-matched controls
were observed after 14 days (1.6-fold) and 21 days (2.2-fold). Acute exposure
to cyclophosphamide did not alter sperm DNA integrity after 28 days; this may
indicate either a decrease in susceptibility to damage or the presence of
repair in early spermiogenic germ cells.
|
Subchronic 4-Day Exposure
Short-term repeat exposure to cyclophosphamide resulted in dose- and
time-dependent increases in DNA damage
(Figure 3). By day 14, no
significant differences were seen between sperm exposed to low doses of
cyclophosphamide and control sperm for any comet parameters. Administration of
a higher dose, however, resulted in significant differences in tail length
(1.6-fold) and tail moment (2.3-fold). Drug-exposed spermatozoa collected on
day 21 showed the highest levels of DNA strand breaks detected at any time
point. Measurements of comet tail moment after exposure to low or high
cyclophosphamide doses were 3.3- and 9.4-fold higher than for the control,
respectively (Figure 3C).
Similar changes were observed for the percentage of tail DNA and tail length;
however, the magnitudes were not as great (low dose: 2.4- and 2.2-fold
increases, respectively; high dose: 3.8-fold increase for both parameters).
Spermatozoa collected on day 28 had relatively lower levels of DNA strand
breaks than spermatozoa collected on day 21.
|
Chronic Exposure
Significant increases in the percentage of tail DNA, tail length, and tail
moment were detected at all time points after chronic exposure to low doses of
cyclophosphamide (Figure 4).
There were significant yet very small differences in the percent tail DNA for
cyclophosphamide-exposed sperm populations at the 3 time points. In contrast,
the mean tail length showed a significant increase in damage from day 14 (80.1
µm) to day 21 (102.8 µm) and then a slight decrease by day 28 (94.2
µm). Tail moments showed a 1.9-fold increase in DNA damage after 14 days;
damage was maximal by 21 days of chronic cyclophosphamide exposure (3.4-fold
increase). In comparison to the mean tail moments observed after low-dose
subchronic exposure (Figure
3C), the mean tail moment values for each time point were much
higher after chronic drug exposure, indicating an accumulation of
cyclophosphamide-induced damage during the entire course of drug
administration. This increase in damage appeared to reach a plateau by day 21,
as there was no difference between the fold increases in damage for days 21
and 28 (3.4- and 3.5-fold increases, respectively).
|
Distribution of Sperm From Low-Damage to High-Damage Groups
Frequency histograms of tail moment represent the distribution of sperm
damage. Tail moments for drug-exposed spermatozoa had a heterogeneous
distribution pattern, ranging from 0 to 100, rather than discrete populations
of low and high DNA damage. Differences in the percentage of sperm with
increasing amounts of damage were, however, still noticeable. An overwhelming
majority (
94%) of tail moments for control animals ranged from 0 to 15;
therefore, in comparison, the percentage of abnormal sperm with tail moments
greater than 15 in drug-treated populations was calculated
(Figure 5).
|
Significant increases in the percentage of abnormal sperm were seen at all time points among the cyclophosphamide-treated group in the high-dose/acute study (Figure 5A). By day 14, 12% of sperm were damaged, while by day 21, 10% of sperm had tail moments above 15. Note that although no significant difference was found between tail moment means of drug-exposed and control sperm at day 28 (Figure 2C), there was still a higher number (14%) of sperm from cyclophosphamide-treated animals with abnormal DNA. For the subchronic cyclophosphamide study, the highest percentage of abnormal sperm was found within the population of cells collected after 21 days for both low and high cyclophosphamide doses (12% and 32%, respectively; Figure 5B). In the day 28 high-dose cyclophosphamide-exposed sperm, significant differences were found, even though the tail moment mean was not significantly different from controls. At days 14 and 28, only sperm collected after high-dose cyclophosphamide administration had a significantly higher than control percentage of sperm with increased DNA damage.
Chronic low-dose administration of cyclophosphamide resulted in a significant increase in the percentage of abnormal sperm compared to controls (Figure 5C). Only 13% of sperm presented with abnormal DNA (2.6-fold increase) by day 14. Cyclophosphamide-induced damage accumulated in 22% of the germ cells that were first exposed during mid-spermiogenesis and collected 21 days later (4.1-fold increase). The percentage of abnormal sperm did not further increase by day 28.
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
The germ cell phase most sensitive to the induction of mutations by cyclophosphamide was the early spermatid phase (Sotomayor and Cumming, 1975). As measured by the comet assay, the mid-spermiogenic germ cells were most susceptible to DNA damage after cyclophosphamide exposure. These data, and those of Haines et al (2002), on germ cell phase–specific susceptibility to radiation damage suggest that the comet assay is not predictive of subtle mutational changes. However, high amounts of DNA damage as detected by the comet assay have been associated with the failure of embryo development after intracytoplasmic sperm injection (Morris et al, 2002) and with infertility in humans (Irvine et al, 2000). The DNA damage measured by the comet assay may also provide an accurate reflection of adverse reproductive outcome after chronic low-dose administration of cyclophosphamide to male rats (Trasler et al, 1985, 1986, 1987).
Cyclophosphamide exposure resulted in dose-dependent and time-specific increases in the levels of DNA damage; as dose and exposure time increased, so did the fraction of cells with DNA damage. Acute exposure to a high dose of cyclophosphamide did not create any major elevations in damage, and the damage that was noted was readily reversible. Step 9 and 15 spermatids collected as spermatozoa on days 21 and 14, respectively, incurred only low levels of damage. Acute cyclophosphamide exposure affected gene expression most dramatically in round spermatids; the expression of DNA repair genes was induced (Aguilar-Mahecha et al, 2001). These data suggest that round spermatids attempt to compensate for DNA damage induced by the drug. Neither acute nor subchronic cyclophosphamide exposure resulted in a significant increase in damage in germ cells exposed to the drug as round spermatids (acute: step 1 spermatids, subchronic: steps 1–5 spermatids). Postmeiotic spermatids do not undergo apoptosis (Cai et al, 1997; Sinha Hikim and Swerdloff, 1999; Brinkworth and Nieschlag, 2000); however, early to mid-spermatids do have the ability to repair DNA lesions (Sega, 1976; Sotomayor et al, 1978) that may give rise to DNA strand breaks. The ultimate effect of cyclophosphamide on germ cells will depend on both the extent of damage and their ability to undergo DNA repair. While there was no significant increase in overall damage at this stage, there was still a discrete population of abnormal sperm presenting increased levels of damage, and these cells may be capable of affecting progeny.
Repeat exposure to cyclophosphamide was required for higher levels of damage to occur. Subchronic treatment of male rats produced maximal damage in elongating spermatids exposed to the drug from stages 9 to 14. Chronic administration of cyclophosphamide resulted in the greatest accumulation of damage over time; the damage reached a plateau after 21 days of drug treatment, at a time point when germ cells exposed to cyclophosphamide are developing from elongating spermatids (steps 9–19) to mature spermatozoa. Cyclophosphamide may exert its maximal effect on elongating spermatids and spermatozoa, since these cells have lost the ability to repair DNA and undergo apoptosis.
Differences in susceptibility to genetic damage between mid- (steps 9–14) and late (steps 15–19) spermatids may be due to chromatin structural changes during spermiogenesis. The structural organization of DNA in the sperm may determine the participation of the paternal genome in embryo development. During spermiogenesis, mammalian sperm DNA is reorganized into loop domains attached at specific sites to the nuclear matrix (Ward and Coffey, 1991; Ward, 1993). The unique chromatin architecture that results may be required to facilitate scheduled transcription after fertilization. DNase-I-hypersensitivity regions have been localized to transcriptionally active or potentially active genes near nuclear matrix attachment sites (Gross and Garrard, 1988). The pattern of DNase-I-hypersensitivity regions changes during spermiogenesis; step 12–13 elongating spermatids are the most sensitive to enzymatic action (McPherson and Longo, 1992). This stage of spermiogenesis may represent a point at which the male genome is more accessible to insult. In comparison, alkylating agents preferentially damage DNA regions that are in close proximity to matrix-bound replication and transcription sites (Muenchen and Pienta, 1999). The template function of spermatozoal DNA was markedly affected after 6 weeks of treatment with cyclophosphamide (Qiu et al, 1995b). During spermiogenesis, certain gene loci may be more susceptible to cyclophosphamide alkylation; we hypothesize that these genes play an important role in regulating early embryo development.
Final packaging of the sperm DNA occurs as histone acetylation and ubiquitination increase in mid-spermiogenic spermatids to allow transition proteins to bind to the DNA. These transition proteins then facilitate the preferential binding of protamines in late spermatids to condense the chromatin (Poccia, 1986; Wouters-Tyrou et al, 1998). Endogenous nicks in DNA, present normally in step 12–13 rat spermatids, are ligated before the completion of protamination (McPherson and Longo 1992, 1993a,b; Sakkas et al, 1995). These nicks may be present to facilitate protamination by providing relief of tortional stress (McPherson and Longo, 1992). Improper ligation of these breaks may result in altered chromatin structure and residual DNA strand breaks in spermatozoa (Sailer et al, 1995; Caron et al, 2001; Kierszenbaum, 2001). The presence of DNA damage in mature spermatozoa has been correlated with poor chromatin packaging (Gorczyca et al, 1993; Sailer, 1995; Manicardi et al, 1998), possibly due to underprotamination (Manicardi et al, 1995; Sakkas et al, 1996). Cyclophosphamide may affect the relationship between protamination and endogenous nick creation and ligation. Thus, cyclophosphamide maximally damages DNA at its most vulnerable state, during mid-spermiogenesis, when nucleoproteins are involved in the histone-protamine exchange.
Decreased iodoacetamide binding, indicating decreased reducible sulfhydryl content of sperm nuclei, was observed in cyclophosphamide-exposed germ cells, suggesting that protamine is affected in these cells (Qiu et al, 1995a). Effects on reducible sulfhydryl content may be due to either incomplete protamine deposition or an increase in alkylation of protamine sulfhydryl groups. Protamines in the testis may be especially susceptible to alkylation; if so, the end result would be blockage of normal disulfide bond formation, thus preventing proper chromatin condensation. This could lead to stress in the chromatin structure and result in DNA strand breaks (Sega and Owens, 1983). Fertilization with damaged or poor-quality sperm may lead to aberrant pronuclear development (Lopes et al, 1998a). Indeed, male pronulear formation was early in rat oocytes sired by cyclophosphamide-treated males (Harrouk et al, 2000b). Sega and Owens (1983) have paralleled patterns of alkylation of protamine in late spermatids and early spermatozoa to the occurrence of dominant lethal mutations.
In summary, cyclophosphamide-induced DNA damage accumulates over time, with the most damaging effects occurring during mid-spermiogenesis. The step 9–14 spermatids appear to be most susceptible to DNA damage; this represents a key time point in sperm chromatin remodeling (histone acetylation and transition protein deposition). Fertilization can be achieved using damaged spermatozoa; however, proper embryo development depends on spermatozoal genetic integrity (Ahmadi and Ng, 1999). In previous studies, using the comet assay, we have shown that cyclophosphamide-exposed spermatozoa imparted significantly greater DNA damage to fertilized eggs at the single-cell stage than did control spermatozoa (Harrouk et al, 2000a). Given the results of the present study, we speculate that cyclophosphamide disrupts chromatin remodeling, hence affecting sperm chromatin structure and embryo development.
|
Footnotes |
|---|
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Ahmadi A, Ng SC. Fertilizing ability of DNA-damaged spermatozoa. J Exp Zool. 1999; 284:696–704.[Medline]
Anderson D, Dhawan A, Yu TW, Plewa MJ. An investigation of bone marrow and testicular cells in vivo using the comet assay. Mutat Res. 1996; 370:159–174.[Medline]
Angelis KJ, Dusinska M, Collins AR. Single cell gel electrophoresis: detection of DNA damage at different levels of sensitivity. Electrophoresis. 1999; 20:2133–2138.[Medline]
Balhorn R. A model for the structure of chromatin in mammalian
sperm. J Cell Biol. 1982; 93:298–305.
Bishop JB, Witt KL, Sloane RA. Genetic toxicities of human teratogens. Mutat Res. 1997; 396:9–43.[Medline]
Brinkworth MH. Paternal transmission of genetic damage: findings in animals and humans. Int J Androl. 2000; 23:123–135.[Medline]
Brinkworth MH, Nieschlag E. Association of cyclophosphamide-induced male-mediated, foetal abnormalities with reduced paternal germ-cell apoptosis. Mutat Res. 2000; 447:149–154.[Medline]
Cai L, Hales BF, Robaire B. Induction of apoptosis in the germ cells of adult male rats after exposure to cyclophosphamide. Biol Reprod. 1997; 56:1490–1497.[Abstract]
Caron N, Veilleux S, Boissonneault G. Stimulation of DNA repair by the spermatidal TP1 protein. Mol Reprod Dev. 2001; 58:437–443.[Medline]
Chatterjee R, Haines GA, Perera DM, Goldstone A, Morris ID.
Testicular and sperm DNA damage after treatment with fludarabine for chronic
lymphocytic leukaemia. Hum Reprod. 2000; 15:762–766.
Clermont Y. Kinetics of spermatogenesis in mammals: seminiferous
epithelium cycle and spermatogonial renewal. Physiol
Rev. 1972; 52:198–236.
Ehling UH. Induction of gene mutations in germ cells of the mouse. Arch Toxicol. 1980; 46:123–138.[Medline]
Ehling UH, Cumming RB, Malling HV. Induction of dominant lethal mutations by alkylating agents in male mice. Mutat Res. 1968; 5:417–428.[Medline]
Generoso WM, Cain KT, Krishna M, Sheu CW, Gryder RM. Heritable translocation and dominant-lethal mutation induction with ethylene oxide in mice. Mutat Res. 1980; 73:133–142.[Medline]
Gorczyca W, Traganos F, Jesionowska H, Darzynkiewicz Z. Presence of DNA strand breaks and increased sensitivity of DNA in situ to denaturation in abnormal human sperm cells: analogy to apoptosis of somatic cells. Exp Cell Res. 1993; 207:202–205.[Medline]
Gross DS, Garrard WT. Nuclease hypersensitive sites in chromatin. Annu Rev Biochem. 1988; 57:159–197.[Medline]
Haines GA, Hendry JH, Daniel CP, Morris ID. Increased levels of comet-detected spermatozoa DNA damage following in vivo isotopic- or X-irradiation of spermatogonia. Mutat Res. 2001; 495:21–32.[Medline]
Haines GA, Hendry JH, Daniel CP, Morris ID. Germ cell and
dose-dependent DNA damage measured by the comet assay in murine spermatozoa
after testicular X-irradiation. Biol Reprod. 2002; 67:854–861.
Haines G, Marples B, Daniel P, Morris I. DNA damage in human and mouse spermatozoa after in vitro-irradiation assessed by the comet assay. Adv Exp Med Biol. 1998; 444:79–91.[Medline]
Harrouk W, Codrington A, Vinson R, Robaire B, Hales BF. Paternal exposure to cyclophosphamide induces DNA damage and alters the expression of DNA repair genes in the rat preimplantation embryo. Mutat Res. 2000a; 461:229–241.[Medline]
Harrouk W, Khatabaksh S, Robaire B, Hales BF. Paternal exposure to cyclophosphamide dysregulates the gene activation program in rat preimplantation embryos. Mol Reprod Dev. 2000b; 57:214–223.[Medline]
Irvine DS, Twigg JP, Gordon EL, Fulton N, Milne PA, Aitken RJ. DNA integrity in human spermatozoa: relationships with semen quality. J Androl. 2000; 21:33–44.[Abstract]
Jackson H. The effects of alkylating agents on fertility.
Br Med Bull. 1964; 20:107–114.
Jenkinson PC, Anderson D. Malformed foetuses and karyotype abnormalities in the offspring of cyclophosphamide and allyl alcohol-treated male rats. Mutat Res. 1990; 229:173–184.[Medline]
Kierszenbaum AL. Transition nuclear proteins during spermiogenesis: unrepaired DNA breaks not allowed. Mol Reprod Dev. 2001; 58:357–358.[Medline]
Koppen G, Angelis KJ. Repair of X-ray induced DNA damage measured by the comet assay in roots of Vicia faba. Environ Mol Mutagen. 1998; 32:281–285.[Medline]
Kusakabe H, Szczygiel MA, Whittingham DG, Yanagimachi R.
Maintenance of genetic integrity in frozen and freeze-dried mouse spermatozoa.
Proc Natl Acad Sci U S A. 2001; 98:13501–13506.
Larson KL, DeJonge CJ, Barnes AM, Jost LK, Evenson DP. Sperm
chromatin structure assay parameters as predictors of failed pregnancy
following assisted reproductive techniques. Hum
Reprod. 2000; 15:1717–1722.
Lopes S, Jurisicova A, Casper RF. Gamete-specific DNA fragmentation
in unfertilized human oocytes after intracytoplasmic sperm injection.
Hum Reprod. 1998a; 13:703–708.
Lopes S, Sun JG, Jurisicova A, Meriano J, Casper RF. Sperm deoxyribonucleic acid fragmentation is increased in poor-quality semen samples and correlates with failed fertilization in intracytoplasmic sperm injection. Fertil Steril. 1998b; 69:528–532.[Medline]
Manicardi GC, Bianchi PG, Pantano S, Azzoni P, Bizzaro D, Bianchi U, Sakkas D. Presence of endogenous nicks in DNA of ejaculated human spermatozoa and its relationship to chromomycin A3 accessibility. Biol Reprod. 1995; 52:864–867.[Abstract]
Manicardi GC, Tombacco A, Bizzaro D, Bianchi U, Bianchi PG, Sakkas D. DNA strand breaks in ejaculated human spermatozoa: comparison of susceptibility to the nick translation and terminal transferase assays. Histochem J. 1998; 30:33–39.[Medline]
McPherson SM, Longo FJ. Localization of DNase I-hypersensitive regions during rat spermatogenesis: stage-dependent patterns and unique sensitivity of elongating spermatids. Mol Reprod Dev. 1992; 31:268–279.[Medline]
McPherson SM, Longo FJ. Chromatin structure-function alterations during mammalian spermatogenesis: DNA nicking and repair in elongating spermatids. Eur J Histochem. 1993a; 37:109–128.[Medline]
McPherson SM, Longo FJ. Nicking of rat spermatid and spermatozoa DNA: possible involvement of DNA topoisomerase II. Dev Biol. 1993b; 158:122–130.[Medline]
Morris ID, Ilott S, Dixon L, Brison DR. The spectrum of DNA damage
in human sperm assessed by single cell gel electrophoresis (Comet assay) and
its relationship to fertilization and embryo development. Hum
Reprod. 2002; 17:990–998.
Muenchen HJ, Pienta KJ. The role of the nuclear matrix in cancer chemotherapy. Crit Rev Eukaryot Gene Expr. 1999; 9:337–343.[Medline]
Olshan AF, Mattison DR, eds. Male Mediated Developmental Toxicity. New York, NY: Plenum Press; 1994 .
Poccia D. Remodeling of nucleoproteins during gametogenesis, fertilization, and early development. Int Rev Cytol. 1986; 105:1–65.[Medline]
Pont J, Albrecht W. Fertility after chemotherapy for testicular germ cell cancer. Fertil Steril. 1997; 68:1–5.[Medline]
Qiu J, Hales BF, Robaire B. Effects of chronic low-dose cyclophosphamide exposure on the nuclei of rat spermatozoa. Biol Reprod. 1995a; 52:33–40.[Abstract]
Qiu J, Hales BF, Robaire B. Damage to rat spermatozoal DNA after chronic cyclophosphamide exposure. Biol Reprod. 1995b; 53:1465–1473.[Abstract]
Robaire B, Hales BF, eds. Advances in Male-Mediated Developmental Toxicity. New York, NY: Kluwer Academic/Plenum Press; 2003.
Russell LB, Hunsicker PR, Cacheiro NL, Bangham JW, Russell WL,
Shelby MD. Chlorambucil effectively induces deletion mutations in mouse germ
cells. Proc Natl Acad Sci U S A. 1989; 86:3704–3708.
Russell LB, Hunsicker PR, Shelby MD. Melphalan, a second chemical for which specific-locus mutation induction in the mouse is maximum in early spermatids. Mutat Res. 1992; 282:151–158.[Medline]
Russell WL, Kelly EM, Hunsicker PR, Bangham JW, Maddux SC, Phipps
EL. Specific-locus test shows ethylnitrosourea to be the most potent mutagen
in the mouse. Proc Natl Acad Sci U S A. 1979; 76:5818–5819.
Sailer BL, Jost LK, Evenson DP. Mammalian sperm DNA susceptibility
to in situ denaturation associated with the presence of DNA strand breaks as
measured by the terminal deoxynucleotidyl transferase assay. J
Androl. 1995; 16:80–87.
Sakkas D, Manicardi G, Bianchi PG, Bizzaro D, Bianchi U. Relationship between the presence of endogenous nicks and sperm chromatin packaging in maturing and fertilizing mouse spermatozoa. Biol Reprod. 1995; 52:1149–1155.[Abstract]
Sakkas D, Urner F, Bianchi PG, Bizzaro D, Wagner I, Jaquenoud N,
Manicardi G, Campana A. Sperm chromatin anomalies can influence decondensation
after intracytoplasmic sperm injection. Hum Reprod. 1996; 11:837–843.
Schilsky RL, Lewis BJ, Sherins RJ, Young RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann Intern Med. 1980; 93:109–114.
Sega GA. Molecular dosimetry of chemical mutagens. Measurement of molecular dose and DNA repair in mammalian germ cells. Mutat Res. 1976; 38:317–326.[Medline]
Sega GA, Owens JG. Methylation of DNA and protamine by methyl methanesulfonate in the germ cells of male mice. Mutat Res. 1983; 111:227–244.[Medline]
Sega GA, Wolfe KW, Owens JG. A comparison of the molecular action of an SN1-type methylating agent, methyl nitrosourea and an SN2-type methylating agent, methyl methanesulfonate, in the germ cells of male mice. Chem Biol Interact. 1981; 33:253–269.[Medline]
Singh NP, Danner DB, Tice RR, McCoy MT, Collins GD, Schneider EL. Abundant alkali-sensitive sites in DNA of human and mouse sperm. Exp Cell Res. 1989; 184:461–470.[Medline]
Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988; 175:184–191.[Medline]
Sinha Hikim AP, Swerdloff RS. Hormonal and genetic control of germ cell apoptosis in the testis. Rev Reprod. 1999; 4:38–47.[Abstract]
Sotomayor RE, Cumming RB. Induction of translocations by cyclophosphamide in different germ cell stages of male mice: cytological characterization and transmission. Mutat Res. 1975; 27:375–388.[Medline]
Sotomayor RE, Sega GA, Cumming RB. Unscheduled DNA synthesis in spermatogenic cells of mice treated in vivo with the indirect alkylating agents cyclophosphamide and mitomen. Mutat Res. 1978; 50:229–240.[Medline]
Sun JG, Jurisicova A, Casper RF. Detection of deoxyribonucleic acid fragmentation in human sperm: correlation with fertilization in vitro. Biol Reprod. 1997; 56:602–607.[Abstract]
Tice RR, Agurell E, Anderson D, et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen. 2000; 35:206–221.[Medline]
Trasler JM, Hales BF, Robaire B. Paternal cyclophosphamide treatment of rats causes fetal loss and malformations without affecting male fertility. Nature. 1985; 316:144–146.[Medline]
Trasler JM, Hales BF, Robaire B. Chronic low dose cyclophosphamide treatment of adult male rats: effect on fertility, pregnancy outcome and progeny. Biol Reprod. 1986; 34:275–283.[Abstract]
Trasler JM, Hales BF, Robaire B. A time-course study of chronic paternal cyclophosphamide treatment in rats: effects on pregnancy outcome and the male reproductive and hematologic systems. Biol Reprod. 1987; 37:317–326.[Abstract]
Ward WS. Deoxyribonucleic acid loop domain tertiary structure in mammalian spermatozoa. Biol Reprod. 1993; 48:1193–1201.[Abstract]
Ward WS, Coffey DS. DNA packaging and organization in mammalian spermatozoa: comparison with somatic cells. Biol Reprod. 1991; 44:569–574.[Abstract]
Wouters-Tyrou D, Martinage A, Chevaillier P, Sautiere P. Nuclear basic proteins in spermiogenesis. Biochimie. 1998; 80:117–128.[Medline]
This article has been cited by other articles:
|
|
 |
|
  A. Carmely, D. Meirow, A. Peretz, M. Albeck, B. Bartoov, and B. Sredni Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice Hum. Reprod., June 1, 2009; 24(6): 1322 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rezvanfar, R. Sadrkhanlou, A Ahmadi, H Shojaei-Sadee, M. Rezvanfar, A Mohammadirad, A Salehnia, and M Abdollahi Protection of cyclophosphamide-induced toxicity in reproductive tract histology, sperm characteristics, and DNA damage by an herbal source; evidence for role of free-radical toxic stress Human and Experimental Toxicology, December 1, 2008; 27(12): 901 - 910. [Abstract] [PDF]
|
|
|
|
|
|
C. O'Flaherty, F. Vaisheva, B.F. Hales, P. Chan, and B. Robaire Characterization of sperm chromatin quality in testicular cancer and Hodgkin's lymphoma patients prior to chemotherapy Hum. Reprod., May 1, 2008; 23(5): 1044 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Barton, B. Robaire, and B. F. Hales DNA Damage Recognition in the Rat Zygote Following Chronic Paternal Cyclophosphamide Exposure Toxicol. Sci., December 1, 2007; 100(2): 495 - 503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Codrington, B. F. Hales, and B. Robaire Chronic Cyclophosphamide Exposure Alters the Profile of Rat Sperm Nuclear Matrix Proteins Biol Reprod, August 1, 2007; 77(2): 303 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vaisheva, G. Delbes, B. F. Hales, and B. Robaire Effects of the Chemotherapeutic Agents for Non-Hodgkin Lymphoma, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), on the Male Rat Reproductive System and Progeny Outcome J Androl, July 1, 2007; 28(4): 578 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.M. Codrington, B.F. Hales, and B. Robaire Exposure of male rats to cyclophosphamide alters the chromatin structure and basic proteome in spermatozoa Hum. Reprod., May 1, 2007; 22(5): 1431 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Delbes, B. F. Hales, and B. Robaire Effects of the Chemotherapy Cocktail Used to Treat Testicular Cancer on Sperm Chromatin Integrity J Androl, March 1, 2007; 28(2): 241 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aguilar-Mahecha, B. F. Hales, and B. Robaire Effects of Acute and Chronic Cyclophosphamide Treatment on Meiotic Progression and the Induction of DNA Double-Strand Breaks in Rat Spermatocytes Biol Reprod, June 1, 2005; 72(6): 1297 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bahadur, O. Ozturk, A. Muneer, R. Wafa, A. Ashraf, N. Jaman, S. Patel, A.W. Oyede, and D.J. Ralph Semen quality before and after gonadotoxic treatment Hum. Reprod., March 1, 2005; 20(3): 774 - 781. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
significantly different from
time-matched low-dose cyclophosphamide group; ¶ significantly different
from dose-matched day 21 cyclophosphamide group (P < .05).
